Proof-of-mechanism has been established for TNG260 based on pharmacodynamic data from on-treatment patient biopsies, with ...

Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 - - Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 - - Cash position ...